FDA Panel Supports Anemia Drugs for Cancer Patients

Related Encyclopedia • Acidophilus • Adenocarcinoma of the Lung and Brain Metastases • Amenorrhea • Amniocentesis More... Related Healthscout Videos New Frontiers in Fertility Complementary Cancer Care A Welcome Message from Survivor PJ Hamel Smother Says "Cut!" More... Related Animations • Breast Reduction • Breast Self-Exam Video • Colon Cancer • Erectile Dysfunction More... Related Drug Information • Actonel • Detrol LA • Diflucan • Ditropan XL More... Related News Articles • School Lunches Too Fatty and Sugary, Critics Say • Ethnicity May Drive Response to Obesity, Insulin Resistance • Half of Black Teens May Be Vitamin D Deficient • Doc-Patient Relationship May Be Key to Quality More...

Page:  << Prev | 1 | 2 | 3

And last week, Amgen agreed to expand the "black box" warning on all three drugs to include information about tumor growth and death in patients with early-stage breast cancer and cervical cancer. Johnson & Johnson markets Procrit in an agreement with Amgen, the Wall Street Journal reported.

When Procrit was first approved in 1989, the drug was touted as a treatment to lessen fatigue and improve quality of life among cancer and HIV patients with anemia, but the revised label states there was no evidence to back that claim. The label change was the fifth such change since Procrit's approval, FDA officials said.

More information

Text Continues Below

---

For more on ESAs, go to the U.S. Food and Drug Administration.

Page:  << Prev | 1 | 2 | 3